Moderna (MRNA) PT Lowered to $108 at UBS
Tweet
Share
E-mailGet Alerts MRNA Hot Sheet
Price: $143.25 -17.85%
Rating Summary:
6 Buy, 21 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Rating Summary:
6 Buy, 21 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Join SI Premium – FREE
UBS analyst Eliana Merle lowered the price target on Moderna (NASDAQ: MRNA) to $108.00 (from $140.00) while maintaining a Buy rating.
You May Also Be Interested In
- BofA Securities Upgrades Moderna (MRNA) to Neutral
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- Nutanix (NTNX) PT Raised to $80 at Oppenheimer Into EPS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
